(Q40973875)

25 September 2017

1 reference

title

Atrial fibrillation: maintenance of sinus rhythm versus rate control (English)

1 reference

25 September 2017

1 reference

Sopher SM

1

1 reference

25 September 2017

Camm AJ

series ordinal

2

1 reference

25 September 2017

language of work or name

English

0 references

publication date

1 January 1996

1 reference

American Journal of Cardiology

25 September 2017

published in

1 reference

25 September 2017

volume

77

1 reference

25 September 2017

issue

3

1 reference

25 September 2017

page(s)

24A-37A

1 reference

Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: complete recovery after restoration of sinus rhythm

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Functional capacity before and after cardioversion of atrial fibrillation: a controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

The natural history of lone atrial fibrillation. A population-based study over three decades

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

What is meant by a "controlled" ventricular rate in atrial fibrillation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Determinants of the ventricular rate during atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Digitalis. Mechanisms of action and clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Digitalis and verapamil in atrial fibrillation and flutter. Is verapamil now the preferred agent?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Digoxin for atrial fibrillation: a drug whose time has gone?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Effects of digitalis on the normal and the failing heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Towards improved control of atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Maximal exercise testing and gas exchange in patients with chronic atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Failure of long-term digitalization to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Clonidine for patients with rapid atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Digoxin or verapamil or metoprolol for heart rate control in patients with mitral stenosis--a randomised cross-over study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Effects of diltiazem, propranolol, and their combination in the control of atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Comparative effects of nadolol-digoxin combination therapy and digoxin monotherapy for chronic atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Improved control of atrial fibrillation with combined pindolol and digoxin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Verapamil improves exercise capacity in chronic atrial fibrillation: double-blind crossover study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Catheter-induced ablation of the atrioventricular junction to control refractory supraventricular arrhythmias.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Catheter technique for closed-chest ablation of the atrioventricular conduction system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Atrial fibrillation in patients with Wolff-Parkinson-White syndrome: incidence after surgical ablation of the accessory pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Frequency of recurrent atrial fibrillation after catheter ablation of overt accessory pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Initiation of atrial fibrillation in the Wolff-Parkinson-White syndrome: the importance of the accessory pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Effects on cardiac performance of atrioventricular node catheter ablation using radiofrequency current for drug-refractory atrial arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Effect of catheter ablation of the atrioventricular junction on quality of life and exercise tolerance in paroxysmal atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Modulation of atrioventricular conduction by ablation of the "slow" atrioventricular node pathway in patients with drug-refractory atrial fibrillation or flutter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Radiofrequency current therapy in atrial tachyarrhythmias: modulation versus ablation of atrioventricular nodal conduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Sinus node-atrioventricular node isolation: long-term results with the "corridor" operation for atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Surgical therapy of paroxysmal atrial fibrillation with the "corridor" operation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

VENTRICULAR RESPONSE IN ATRIAL FIBRILLATION. ROLE OF CONCEALED CONDUCTION IN THE AV JUNCTION

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Effect of right ventricular pacing on ventricular rhythm during atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

A new pacing method for rapid regularization and rate control in atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Intravenous flecainide acetate for supraventricular tachycardias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Cardioversion with flecainide in patients with atrial fibrillation of recent onset

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Efficacy of i.v. amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Intravenous amiodarone for conversion of atrial fibrillation to sinus rhythm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Rapid control of refractory atrial tachyarrhythmias with high-dose oral amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

The use of quinidine in cardioversion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

A randomized comparison of external and internal cardioversion of chronic atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Electrical reversion of cardiac arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Developments, complications and limitations of catheter-mediated electrical ablation of posterior accessory atrioventricular pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Initial experience with intracardiac atrial defibrillation in patients with chronic atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Maintenance of sinus rhythm after DC reversion of atrial fibrilllation. A double-blind controlled trial of long-acting quinidine bisulphate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation. A controlled clinical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Value of quinidine in maintenance of sinus rhythm after electric conversion of atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Maintenance of sinus rhythm after atrial defibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Proarrhythmia in patients treated for atrial fibrillation or flutter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Antiarrhythmic drugs in the management of atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Long-term results of DC reversion of atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

The cardiac arrhythmia suppression trial (CAST)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

The hazards of using type 1C antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Usefulness of propafenone for recurrent paroxysmal atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Beta-blocking therapy in atrial and ventricular tachyarrhythmias: experience with nadolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Radiofrequency catheter ablation of the atria reduces inducibility and duration of atrial fibrillation in dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Successful catheter ablation of atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

DDD pacing: an effective treatment modality for recurrent atrial arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

Effect of Oral Verapamil on Ventricular Irregularity in Long-Standing Atrial Fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Ventricular fibrillation in the Wolff-Parkinson-White syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Does cardioversion of atrial fibrillation result in myocardial damage?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989115-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(97)89115-1

1 reference

25 September 2017

1 reference